Cytiva Completes $1.6 Billion Global Manufacturing Expansion to Boost Biopharmaceutical Supply Chain
核心洞察
Cytiva (搜索) has completed major expansion projects across the United States, Europe, and Asia as part of a $1.6 billion investment plan running through 2028 to enhance biopharmaceutical manufacturing capacity.
The company has doubled chromatography resins production capacity in Uppsala, Sweden, and is establishing new manufacturing sites in Michigan and expanding filtration capabilities across multiple locations.
These expansions follow an "in-region for-region" manufacturing strategy designed to provide faster delivery of critical supplies including chromatography resins, filtration systems, and cell culture media to biopharmaceutical customers worldwide.
Cytiva (搜索), a Danaher (搜索) company, has completed significant expansion projects across multiple continents as part of a comprehensive $1.6 billion investment plan designed to strengthen the global biopharmaceutical supply chain. The biotechnology firm's expansion strategy, which continues through 2028, aims to increase manufacturing capacity, ensure faster delivery of critical supplies, and support biopharmaceutical companies in bringing life-changing therapies to market.
Chromatography and Filtration Manufacturing Expansion
The company has made substantial investments in chromatography resins and filtration capabilities across its global network. In Uppsala, Sweden, Cytiva (搜索) has approximately doubled its production capacity for chromatography resins manufacturing through the construction of new factories and installation of new equipment. The Swedish facility has also benefited from improved automation capabilities and a new tank farm for solvent storage.
To enhance North American supply capabilities, Cytiva (搜索) has constructed a second resins manufacturing site in Muskegon, Michigan, employing approximately 100 full-time associates. The facility is scheduled to be fully operational by the end of 2028, with plans to hire about 100 additional associates.
The company's filtration manufacturing expansion spans multiple regions. In Pensacola, Florida, new filtration manufacturing lines will increase production capacity for filter membranes for North America by 20% by August 2025. The facility will maintain its most-ordered products in stock for immediate availability.
Regional Capacity Improvements
Cytiva (搜索)'s global expansion includes significant capacity improvements across established manufacturing sites. In Fajardo, Puerto Rico, upgrades and expansions in filtration manufacturing have improved capacity by 33%. Similarly, expanded filtration device manufacturing in Ilfracombe, UK, has enhanced capacity by 81%.
The company is also addressing growing demand in the Asia-Pacific region by initiating filtration manufacturing at its Innovation Hub and manufacturing facility in South Korea, beginning in 2026. This expansion specifically targets increased demand for high-quality filtration solutions in the region.
Single-Use and Cell Culture Media Manufacturing
The investment plan includes substantial expansion of single-use consumable manufacturing capacity. In Beijing, China, Cytiva (搜索) has tripled its single-use consumable manufacturing capacity, while doubling manufacturing capacity in Duncan, South Carolina. The company maintains sustained manufacturing capacity in Medemblik, Netherlands.
In North America, Cytiva (搜索) is expanding access to cell culture media by increasing dry powder and liquid media manufacturing capacity in Logan, Utah, for large volumes while adding high-speed bottle filling capabilities for small volumes. The Logan facility features an expanded staging area for finished goods and a new centralized 10,000 square-foot quality control laboratory, with an additional 73,850 square feet of expansions scheduled through 2026.
Strategic Supply Chain Enhancement
Pierre-Alain Ruffieux, chief operating officer at Cytiva (搜索), emphasized the critical importance of supply chain reliability in biopharmaceutical manufacturing. "A robust supply chain is critical to our customers so they can deliver life-changing therapies to patients around the world," Ruffieux stated. "We have increased our global manufacturing capacity, with a focus on in-region for-region, to meet the demands and best serve the customer."
The expansion strategy reflects Cytiva (搜索)'s commitment to supporting biopharmaceutical companies through improved delivery times and enhanced manufacturing capabilities. Ruffieux added, "In addition to Cytiva's intense improvement work supported by the Danaher (搜索) Business System, these capacity expansions demonstrate an unparalleled commitment to helping customers make progress to bring therapies to their patients."
The comprehensive investment program, which began in 2019, positions Cytiva (搜索) to better serve the growing global demand for biopharmaceutical manufacturing solutions while maintaining quality standards and reducing supply chain risks for its customers.